Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement

Ads

You May Also Like

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with ...

Publishing of Orion Corporation’s Interim Report for January-March 2017 on 26 April 2017

ORION CORPORATION         STOCK EXCHANGE RELEASE 12 APRIL 2017 at 12.00 noon EEST                       Publishing ...

G1 Therapeutics Announces Pricing of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., May 16, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a ...